Hepatobiliary & Pancreatic Diseases International最新文献

英文中文

eIF3f plays diagnostic and prognostic roles in hepatocellular carcinoma eIF3f在肝细胞癌中具有诊断和预后作用。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-12-18 DOI: 10.1016/j.hbpd.2025.12.013

Hong-Yuan Yi , You-Kang Chen , Hai-Feng Xu

引用次数: 0

Laparoscopic liver resection is superior to open liver resection for hepatocellular carcinoma patients with BCLC stage 0-A hepatocellular carcinoma and portal hypertension 对于BCLC 0-A期肝细胞癌合并门静脉高压症患者，腹腔镜肝切除术优于开放肝切除术。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-12-02 DOI: 10.1016/j.hbpd.2025.12.001

Wu-Gui Yang , Bin Liang , Yu-Fu Peng, Yu-Bo Yang, Ya-Ni Liu, Bo Li, Yong-Gang Wei, Fei Liu

Background

According to the 2022 update of the BCLC strategy, laparoscopic liver resection (LLR) is considered feasible for BCLC stage 0-A hepatocellular carcinoma (HCC) patients with clinically significant portal hypertension (CSPH). However, there is still no research to explore the outcomes of laparoscopic versus open liver resection (OLR) in the specific patients with BCLC stage 0-A HCC and CSPH.

Methods

Patients diagnosed with BCLC stage 0-A HCC and CSPH who underwent liver resection at West China Hospital of Sichuan University from February 2018 to December 2022 were analyzed. Demographic characteristics, pathological findings and postoperative outcomes were compared using propensity score matching (PSM). Long-term outcomes after surgery were analyzed using Kaplan-Meier analysis both before and after PSM.

Results

A total of 409 patients, including 261 LLRs and 148 OLRs, were enrolled in this study. There were imbalances between the groups in baseline information. After 1:1 PSM, 118 patients were included in each group with comparable baseline characteristics. Patients in the LLR group had significantly less intraoperative blood loss compared to those in the OLR group (median 223 vs. 318 mL, P < 0.001), and fewer postoperative complications (33.9% vs. 57.6%, P < 0.001), including lower rates of postoperative liver decompensation (16.9% vs. 28.0%, P = 0.043), postoperative ascites (18.6% vs. 31.4%, P = 0.024) and pulmonary infections (12.7% vs. 29.7%, P = 0.001). The long-term follow-up showed that overall survival (P = 0.154) and recurrence-free survival (P = 0.376) were comparable between the two groups. In subgroup analysis, patients with PLT ≤ 75 × 10⁹/L suffered more postoperative liver decompensation (PLD) and ascites than patiens with PLT > 75 × 10⁹/L.

Conclusions

Compared with OLR, LLR had less intraoperative blood loss, fewer postoperative complications and comparable oncological outcomes for patients with BCLC stage 0/A HCC and CSPH.

背景：根据2022年更新的BCLC策略，腹腔镜肝切除术（LLR）被认为是可行的BCLC 0-A期肝细胞癌（HCC）患者临床显著门脉高压（CSPH）。然而，目前还没有研究探讨腹腔镜与开放肝切除术（OLR）在特定BCLC 0-A期HCC和CSPH患者中的疗效。方法：对2018年2月至2022年12月在四川大学华西医院行肝切除术的BCLC 0-A期HCC和CSPH患者进行分析。使用倾向评分匹配（PSM）比较人口学特征、病理结果和术后结果。采用Kaplan-Meier分析PSM前后术后远期疗效。结果：共纳入409例患者，其中llr 261例，olr 148例。两组之间在基线信息上存在不平衡。1:1 PSM后，每组118例患者具有可比的基线特征。与OLR组相比，LLR组患者术中出血量明显减少（中位数223比318 mL， P < 0.001），术后并发症较少（33.9 %比57.6 %,P < 0.001），包括术后肝失代偿率较低（16.9 %比28.0 %,P = 0.043），术后腹水（18.6 %比31.4 %,P = 0.024）和肺部感染（12.7 %比29.7 %,P = 0.001）。长期随访显示，两组患者总生存率（P = 0.154）和无复发生存率（P = 0.376）具有可比性。在亚组分析中，PLT≤75 × 109/L的患者术后肝失代偿（PLD）和腹水发生率高于PLT≤75 × 109/L的患者。结论：与OLR相比，LLR术中出血量少，术后并发症少，BCLC 0/A期HCC和CSPH患者的肿瘤预后相似。

{"title":"Laparoscopic liver resection is superior to open liver resection for hepatocellular carcinoma patients with BCLC stage 0-A hepatocellular carcinoma and portal hypertension","authors":"Wu-Gui Yang , Bin Liang , Yu-Fu Peng, Yu-Bo Yang, Ya-Ni Liu, Bo Li, Yong-Gang Wei, Fei Liu","doi":"10.1016/j.hbpd.2025.12.001","DOIUrl":"10.1016/j.hbpd.2025.12.001","url":null,"abstract":"<div><h3>Background</h3><div>According to the 2022 update of the BCLC strategy, laparoscopic liver resection (LLR) is considered feasible for BCLC stage 0-A hepatocellular carcinoma (HCC) patients with clinically significant portal hypertension (CSPH). However, there is still no research to explore the outcomes of laparoscopic versus open liver resection (OLR) in the specific patients with BCLC stage 0-A HCC and CSPH.</div></div><div><h3>Methods</h3><div>Patients diagnosed with BCLC stage 0-A HCC and CSPH who underwent liver resection at West China Hospital of Sichuan University from February 2018 to December 2022 were analyzed. Demographic characteristics, pathological findings and postoperative outcomes were compared using propensity score matching (PSM). Long-term outcomes after surgery were analyzed using Kaplan-Meier analysis both before and after PSM.</div></div><div><h3>Results</h3><div>A total of 409 patients, including 261 LLRs and 148 OLRs, were enrolled in this study. There were imbalances between the groups in baseline information. After 1:1 PSM, 118 patients were included in each group with comparable baseline characteristics. Patients in the LLR group had significantly less intraoperative blood loss compared to those in the OLR group (median 223 vs. 318 mL, <em>P</em> < 0.001), and fewer postoperative complications (33.9% vs. 57.6%, <em>P</em> < 0.001), including lower rates of postoperative liver decompensation (16.9% vs. 28.0%, <em>P</em> = 0.043), postoperative ascites (18.6% vs. 31.4%, <em>P</em> = 0.024) and pulmonary infections (12.7% vs. 29.7%, <em>P</em> = 0.001). The long-term follow-up showed that overall survival (<em>P</em> = 0.154) and recurrence-free survival (<em>P</em> = 0.376) were comparable between the two groups. In subgroup analysis, patients with PLT ≤ 75 × 10<sup>9</sup>/L suffered more postoperative liver decompensation (PLD) and ascites than patiens with PLT > 75 × 10<sup>9</sup>/L.</div></div><div><h3>Conclusions</h3><div>Compared with OLR, LLR had less intraoperative blood loss, fewer postoperative complications and comparable oncological outcomes for patients with BCLC stage 0/A HCC and CSPH.</div></div>","PeriodicalId":55059,"journal":{"name":"Hepatobiliary & Pancreatic Diseases International","volume":"25 1","pages":"Pages 32-41"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute liver failure caused by amino acid or organic acid related inborn errors of metabolism 氨基酸或有机酸相关的先天性代谢错误引起的急性肝衰竭。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-06-18 DOI: 10.1016/j.hbpd.2025.06.003

Ying Zhou, Chi Chen, Xin Yang

引用次数: 0

Combined liver resection and peritoneal stripping for Echinococcus multilocularis 肝切除联合腹膜剥离治疗多房棘球蚴。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-12-02 DOI: 10.1016/j.hbpd.2025.12.002

Kaitlyn R Musto, Kristopher P Croome

引用次数: 0

A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma 预测肝癌肝移植后无复发生存的无创决策树。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-11-04 DOI: 10.1016/j.hbpd.2025.11.001

Mo-Dan Yang , Jian-Yong Zhuo , Guo-Ying Wang , Li Zhuang , Xiao Xu , Shu-Sen Zheng , Yang Yang , Di Lu

Background

Liver transplantation (LT) provides an option to radically eliminate hepatocellular carcinoma (HCC) on the premise that recipients are thoroughly evaluated for posttransplant tumor recurrence risk before operation. This study aimed to optimize the Milan criteria (MC) by combining circulating prognostic markers, including interleukin-6 (IL-6) and alpha-fetoprotein (AFP).

Methods

We retrospectively enrolled 449 HCC cases receiving LT in three medical centers in China and divided them into the training cohort (n = 254) and the validation cohort (n = 195). Cox regression analysis was applied to identify recurrence-related risk factors based on patients’ clinical and pathological characteristics, pretransplant plasma IL-6 and AFP levels. The collaborative prediction method was presented in the form of a decision tree. Kaplan-Meier analysis showed the predictive results of independent risk factors and the newly established prediction tree.

Results

In the training cohort (n = 254), we established a predictive decision tree based on three independent risk factors: pretransplant plasma IL-6 (> 15 pg/mL), AFP (> 60 ng/mL), and the MC (beyond the MC), and named it as MIA (MC-IL-6-AFP) tree. According to the MIA tree, patients beyond the MC but with IL-6 ≤ 15 pg/mL and AFP ≤ 60 ng/mL (n = 39) had comparable 3-year recurrence-free survival (RFS) rates as patients within the MC (n = 121): 66.8% vs. 74.7% (P = 0.520). Likely, in the validation cohort (n = 195), the 3-year RFS rates of patients beyond the MC but with IL-6 ≤ 15 pg/mL and AFP ≤ 60 ng/mL (n = 26) were close to those of patients within the MC (n = 87): 71.8% vs. 76.6% (P = 0.660).

Conclusions

We proposed that pretransplant plasma IL-6 and AFP were valid prognostic biomarkers for HCC-related LT. The MIA tree could refine the MC by combining IL-6 and AFP and define an extra subset of eligible candidates without significant sacrifice in RFS.

背景：肝移植（LT）提供了一种从根本上消除肝细胞癌（HCC）的选择，前提是术前对受者进行彻底的移植后肿瘤复发风险评估。本研究旨在通过结合循环预后标志物，包括白细胞介素-6 （IL-6）和甲胎蛋白（AFP），优化米兰标准（MC）。方法：我们回顾性地纳入了中国3个医疗中心接受肝移植的449例HCC患者，并将其分为培训组（n = 254）和验证组（n = 195）。结合患者的临床病理特征、移植前血浆IL-6、AFP水平，采用Cox回归分析确定复发相关危险因素。以决策树的形式提出了协同预测方法。Kaplan-Meier分析显示了独立危险因素和新建立的预测树的预测结果。结果：在训练队列（n = 254）中，我们基于移植前血浆IL-6 （> 15 pg/mL）、AFP （> 60 ng/mL）和MC（超过MC）三个独立的危险因素建立了预测决策树，并将其命名为MIA （MC-IL-6-AFP）树。根据MIA树，MC以外但IL-6≤15 pg/mL和AFP≤60 ng/mL的患者（n = 39）与MC内患者（n = 121）的3年无复发生存率（RFS）相当：66.8% vs. 74.7% （P = 0.520）。在验证队列（n = 195）中，IL-6≤15 pg/mL和AFP≤60 ng/mL的MC以外患者（n = 26）的3年RFS率与MC内患者（n = 87）接近：71.8% vs. 76.6% （P = 0.660）。结论：我们提出移植前血浆IL-6和AFP是hcc相关lt的有效预后生物标志物。MIA树可以通过结合IL-6和AFP来完善MC，并在不显著牺牲RFS的情况下定义一个额外的合格候选子集。

{"title":"A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma","authors":"Mo-Dan Yang , Jian-Yong Zhuo , Guo-Ying Wang , Li Zhuang , Xiao Xu , Shu-Sen Zheng , Yang Yang , Di Lu","doi":"10.1016/j.hbpd.2025.11.001","DOIUrl":"10.1016/j.hbpd.2025.11.001","url":null,"abstract":"<div><h3>Background</h3><div>Liver transplantation (LT) provides an option to radically eliminate hepatocellular carcinoma (HCC) on the premise that recipients are thoroughly evaluated for posttransplant tumor recurrence risk before operation. This study aimed to optimize the Milan criteria (MC) by combining circulating prognostic markers, including interleukin-6 (IL-6) and alpha-fetoprotein (AFP).</div></div><div><h3>Methods</h3><div>We retrospectively enrolled 449 HCC cases receiving LT in three medical centers in China and divided them into the training cohort (<em>n</em> = 254) and the validation cohort (<em>n</em> = 195). Cox regression analysis was applied to identify recurrence-related risk factors based on patients’ clinical and pathological characteristics, pretransplant plasma IL-6 and AFP levels. The collaborative prediction method was presented in the form of a decision tree. Kaplan-Meier analysis showed the predictive results of independent risk factors and the newly established prediction tree.</div></div><div><h3>Results</h3><div>In the training cohort (<em>n</em> = 254), we established a predictive decision tree based on three independent risk factors: pretransplant plasma IL-6 (> 15 pg/mL), AFP (> 60 ng/mL), and the MC (beyond the MC), and named it as MIA (MC-IL-6-AFP) tree. According to the MIA tree, patients beyond the MC but with IL-6 ≤ 15 pg/mL and AFP ≤ 60 ng/mL (<em>n</em> = 39) had comparable 3-year recurrence-free survival (RFS) rates as patients within the MC (<em>n</em> = 121): 66.8% vs. 74.7% (<em>P</em> = 0.520). Likely, in the validation cohort (<em>n</em> = 195), the 3-year RFS rates of patients beyond the MC but with IL-6 ≤ 15 pg/mL and AFP ≤ 60 ng/mL (<em>n</em> = 26) were close to those of patients within the MC (<em>n</em> = 87): 71.8% vs. 76.6% (<em>P</em> = 0.660).</div></div><div><h3>Conclusions</h3><div>We proposed that pretransplant plasma IL-6 and AFP were valid prognostic biomarkers for HCC-related LT. The MIA tree could refine the MC by combining IL-6 and AFP and define an extra subset of eligible candidates without significant sacrifice in RFS.</div></div>","PeriodicalId":55059,"journal":{"name":"Hepatobiliary & Pancreatic Diseases International","volume":"25 1","pages":"Pages 23-31"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exosome-mediated regulation of macrophage polarization: A novel therapeutic strategy for diabetic wound healing 外泌体介导的巨噬细胞极化调节：糖尿病伤口愈合的新治疗策略。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-05-30 DOI: 10.1016/j.hbpd.2025.05.005

Jia-Le Ma , Ling-Xiao Wang , Hao Yu , Zhi-Kang Zhu , Jia-Hong Xu , Jia-Qi Lou , Shou-Jie Wang

引用次数: 0

Non-invasive diagnostic biomarkers of viral hepatitis based on multi-omics technology: Recent advances and challenges 基于多组学技术的病毒性肝炎非侵入性诊断生物标志物：最新进展和挑战。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-10-28 DOI: 10.1016/j.hbpd.2025.10.010

Xiang-Yan Liu , Jian-Fang Lu , Zhuo-Yi Wang , Shu-Sen Zheng

Liver is prone to viral infection. Viral hepatitis can be roughly divided into hepatitis A, B, C, D and E. Accurate diagnosis of viral hepatitis is crucial for accurate treatments. Different types of biomarkers, including non-invasive biomarkers have been explored for the diagnosis of viral hepatitis. With the fast development of multi-omics technology, non-invasive biomarkers can be detected from blood, saliva, urine, stool, and other body fluids. The advantages of non-invasive biomarkers are: 1) non-invasive; 2) convenient to test and 3) repeatable. The application of non-invasive biomarkers significantly improves the diagnostic accuracy of viral hepatitis. The non-invasive biomarkers can be sugars, proteins, nucleic acids, and even microorganisms. In this review, we summarized recent advances in identifying non-invasive biomarkers using multi-omics technology and discussed their potential diagnostic values for viral hepatitis.

肝脏容易受到病毒感染。病毒性肝炎大致可分为甲型、乙型、丙型、丁型和戊型。病毒性肝炎的准确诊断对于准确治疗至关重要。不同类型的生物标志物，包括非侵入性生物标志物，已被探索用于病毒性肝炎的诊断。随着多组学技术的快速发展，非侵入性生物标志物可以从血液、唾液、尿液、粪便和其他体液中检测到。非侵入性生物标志物的优点有：1)非侵入性；2)便于测试，3)可重复。非侵入性生物标志物的应用显著提高了病毒性肝炎的诊断准确性。非侵入性生物标志物可以是糖、蛋白质、核酸，甚至微生物。在这篇综述中，我们总结了利用多组学技术识别非侵入性生物标志物的最新进展，并讨论了它们在病毒性肝炎诊断中的潜在价值。

引用次数: 0

Meetings and Courses 会议及课程

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2026-01-20 DOI: 10.1016/S1499-3872(25)00238-3

引用次数: 0

Yttrium-90 radioembolization therapy prior to liver transplantation for hepatocellular carcinoma improves patient outcomes 肝细胞癌肝移植前的钇-90放射栓塞治疗可改善患者预后。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-11-04 DOI: 10.1016/j.hbpd.2025.11.003

Rui Tang, Guang-Dong Wu, Ang Li, Yu-Cheng Hou, Xuan Tong, Qian Lu

For early hepatocellular carcinoma (HCC), curative therapies include surgical excision and radiofrequency ablation. Other treatment modes for advanced HCC involve transarterial chemoembolization. For HCC patients who do not fit the Milan criteria or are waiting for liver transplantation (LT), studies of transarterial radioembolization with Yttrium-90 (Y-90) demonstrated that Y-90 may accomplish a good downstaging or bridging effect before LT and can even achieve complete pathological necrosis. The present review discussed Y-90 radioembolization as a local regional treatment option for advanced and unresectable HCC, with a focus on neoadjuvant intervention before LT.

对于早期肝细胞癌（HCC），治疗方法包括手术切除和射频消融。晚期HCC的其他治疗方式包括经动脉化疗栓塞。对于不符合米兰标准或等待肝移植（LT）的HCC患者，经动脉放射栓塞钇-90 （Y-90）的研究表明，Y-90可以在肝移植前实现良好的降分期或桥接作用，甚至可以实现完全的病理坏死。本综述讨论了Y-90放射栓塞作为晚期和不可切除的HCC的局部局部治疗选择，重点是肝移植前的新辅助干预。

引用次数: 0

Safety and oncologic outcomes of open versus minimally invasive distal pancreatectomy for resectable pancreatic body and tail cancer 开放与微创远端胰腺切除术治疗可切除胰腺体和尾癌的安全性和肿瘤学结果。

IF 4.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Hepatobiliary & Pancreatic Diseases International

Pub Date : 2026-02-01 Epub Date: 2025-10-28 DOI: 10.1016/j.hbpd.2025.10.007

Hajime Imamura, Tomohiko Adachi, Ayaka Kinoshita, Takashi Hamada, Hajime Matsushima, Takanobu Hara, Akihiko Soyama, Susumu Eguchi

Background

Minimally invasive distal pancreatectomy (MIDP) is increasingly being used, although its oncologic safety for pancreatic ductal adenocarcinoma (PDAC) remains controversial. In Japan, MIDP for PDAC has limited endorsement due to insufficient data. This study aimed to compare the perioperative and long-term outcomes of open distal pancreatectomy (ODP) and MIDP for PDAC.

Methods

We retrospectively analyzed patients with resectable pancreatic body and tail cancer treated with ODP or MIDP (laparoscopic or robotic) between January 2007 and July 2022. The surgical procedures (ODP and MIDP) were compared and the patient characteristics, perioperative outcomes, and long-term outcomes were analyzed. We also compared the outcomes of patients with neoadjuvant chemotherapy (NAC) and without NAC.

Results

A total of 72 distal pancreatectomies were performed (37 ODPs and 35 MIDPs). In the upfront group, MIDP resulted in significantly less blood loss than ODP (P < 0.01), despite similar operative time. There was no statistically significant difference in the 2-year recurrence-free survival (RFS) rates between ODP and MIDP (39.7% vs. 57.8%, P = 0.60) or in the overall survival (OS) rates (66.7% vs. 74.1%, P = 0.43). Similarly, in the NAC group, MIDP resulted in significantly less blood loss than ODP (P = 0.01); ODP and MIDP had similar 2-year RFS rates (41.7% and 60.0%, P = 0.75) and OS rates (50.0% and 70.0%, P = 0.36). The interval from surgery to adjuvant chemotherapy initiation did not significantly differ between the ODP and MIDP subgroups in both the upfront group (P = 0.13) and the NAC group (P = 0.14). The incidence of recurrence was 64.8% for ODP and 42.8% for MIDP (P = 0.06). Both procedures showed similar distributions of local and distant recurrence.

Conclusions

MIDP caused less blood loss and had similar oncologic safety compared with ODP. MIDP could become a feasible, minimally invasive option with sufficient oncologic safety for pancreatic body and tail cancers.

背景：微创远端胰腺切除术（MIDP）越来越多地被应用，尽管其在胰腺导管腺癌（PDAC）中的肿瘤学安全性仍存在争议。在日本，由于数据不足，MIDP对PDAC的认可有限。本研究旨在比较开放式远端胰腺切除术（ODP）和MIDP治疗PDAC的围手术期和远期疗效。方法：回顾性分析2007年1月至2022年7月期间采用ODP或MIDP（腹腔镜或机器人）治疗的可切除胰腺体尾癌患者。比较两种手术方式（ODP和MIDP），分析患者特征、围手术期结局和远期结局。我们还比较了接受新辅助化疗（NAC）和未接受新辅助化疗的患者的预后。结果：共行72例远端胰腺切除术（odp 37例，midp 35例）。在前期组，尽管手术时间相似，但MIDP导致的出血量明显少于ODP （P < 0.01）。ODP和MIDP的2年无复发生存率（RFS）（39.7% vs. 57.8%, P = 0.60）和总生存率（OS）（66.7% vs. 74.1%, P = 0.43）差异无统计学意义。同样，在NAC组中，MIDP导致的失血量明显少于ODP (P = 0.01)；ODP和MIDP的2年RFS率（41.7%和60.0%,P = 0.75）和OS率（50.0%和70.0%,P = 0.36）相似。术前组（P = 0.13）和NAC组（P = 0.14）的ODP和MIDP亚组之间从手术到辅助化疗开始的时间间隔无显著差异。ODP和MIDP的复发率分别为64.8%和42.8% （P = 0.06）。两种手术均表现出相似的局部和远处复发分布。结论：与ODP相比，MIDP的失血量更少，肿瘤安全性相似。MIDP可能成为一种可行的、微创的选择，对胰腺体癌和尾癌具有足够的肿瘤学安全性。

{"title":"Safety and oncologic outcomes of open versus minimally invasive distal pancreatectomy for resectable pancreatic body and tail cancer","authors":"Hajime Imamura, Tomohiko Adachi, Ayaka Kinoshita, Takashi Hamada, Hajime Matsushima, Takanobu Hara, Akihiko Soyama, Susumu Eguchi","doi":"10.1016/j.hbpd.2025.10.007","DOIUrl":"10.1016/j.hbpd.2025.10.007","url":null,"abstract":"<div><h3>Background</h3><div>Minimally invasive distal pancreatectomy (MIDP) is increasingly being used, although its oncologic safety for pancreatic ductal adenocarcinoma (PDAC) remains controversial. In Japan, MIDP for PDAC has limited endorsement due to insufficient data. This study aimed to compare the perioperative and long-term outcomes of open distal pancreatectomy (ODP) and MIDP for PDAC.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed patients with resectable pancreatic body and tail cancer treated with ODP or MIDP (laparoscopic or robotic) between January 2007 and July 2022. The surgical procedures (ODP and MIDP) were compared and the patient characteristics, perioperative outcomes, and long-term outcomes were analyzed. We also compared the outcomes of patients with neoadjuvant chemotherapy (NAC) and without NAC.</div></div><div><h3>Results</h3><div>A total of 72 distal pancreatectomies were performed (37 ODPs and 35 MIDPs). In the upfront group, MIDP resulted in significantly less blood loss than ODP (<em>P</em> < 0.01), despite similar operative time. There was no statistically significant difference in the 2-year recurrence-free survival (RFS) rates between ODP and MIDP (39.7% vs. 57.8%, <em>P</em> = 0.60) or in the overall survival (OS) rates (66.7% vs. 74.1%, <em>P</em> = 0.43). Similarly, in the NAC group, MIDP resulted in significantly less blood loss than ODP (<em>P</em> = 0.01); ODP and MIDP had similar 2-year RFS rates (41.7% and 60.0%, <em>P</em> = 0.75) and OS rates (50.0% and 70.0%, <em>P</em> = 0.36). The interval from surgery to adjuvant chemotherapy initiation did not significantly differ between the ODP and MIDP subgroups in both the upfront group (<em>P</em> = 0.13) and the NAC group (<em>P</em> = 0.14). The incidence of recurrence was 64.8% for ODP and 42.8% for MIDP (<em>P</em> = 0.06). Both procedures showed similar distributions of local and distant recurrence.</div></div><div><h3>Conclusions</h3><div>MIDP caused less blood loss and had similar oncologic safety compared with ODP. MIDP could become a feasible, minimally invasive option with sufficient oncologic safety for pancreatic body and tail cancers.</div></div>","PeriodicalId":55059,"journal":{"name":"Hepatobiliary & Pancreatic Diseases International","volume":"25 1","pages":"Pages 83-90"},"PeriodicalIF":4.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Hepatobiliary & Pancreatic Diseases International

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀